Description: Prescient Therapeutics Limited is a clinical-stage oncology company. The Company is engaged in the preparation for and conduct of clinical trials relating to the companies drugs; business development associated with the promotion of its technologies and products, and business development associated with developing collaborative, partnership relationships and corporate transactions. The Company is engaged in developing compounds to treat a range of solid and hematological cancers. It is pursuing the clinical and commercial development of two cancer compounds: PTX-200 and PTX-100. PTX-200 inhibits a tumor survival pathway, which plays a key role in the development of cancers. PTX-100 is a drug that kills cancer cells by blocking geranylgeranyl ransferase-1 (GGT-1). PTX-200 is in Phase Ib/IIa trials in breast and ovarian cancers, and focuses on an accruing patient for leukemia trials. PTX-100 is in Phase I of its clinical trials for breast cancer and multiple Myeloma.
Home Page: ptxtherapeutics.com
PTX Technical Analysis
100 Albert Road
Melbourne,
VIC
3205
Australia
Phone:
61 3 9692 7222
Officers
| Name | Title |
|---|---|
| Mr. Steven Lee Yatomi-Clarke | MD, CEO & Director |
| Ms. Melanie Jaye Leydin B.Bus, C.A., CA | CFO & Company Sec. |
| Ms. Leanne West | Director of Clinical Affairs & Operations |
| Dr. Terrence G. Chew | Chief Medical Officer |
| Ms. Rebecca Lim | Sr. VP of Scientific Affairs |
Exchange: AU
Country: AU
Currency: Australian Dollar (A$)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 6.0139 |
| Price-to-Sales TTM: | 47.6396 |
| IPO Date: | |
| Fiscal Year End: | June |
| Full Time Employees: | 0 |